Market news

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.Fireside Chat at 2:35 p.m. ET The live webcast of the fireside chat will

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura’s new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura’s new Chief Operating Officer, and Julie Person, Aura’s new C

Tipranks Press Release.

Phase 3 CoMpass trial fully enrolled with 108 patients, exceeding enrollment target; on track for topline data in 2H 2027 Strategic operating plan refined to focus on development of bel-sar in ocular oncology Interim NMIBC data reinforce bel-sar’s potential for durable efficacy and favorable safety profile; NMIBC program being strategically deprioritized to focus company resources on ocular oncology Organizational restructuring and disciplined capital allocation strategy to align with ocular onc

Aura Biosciences (AURA) reported a Q2 loss Tuesday of $0.48 per diluted share, compared with a loss

Detailed price information for Aura Biosciences Inc (AURA-Q) from The Globe and Mail including charting and trades.

US stock futures higher, Deckers Outdoor shares fall after reporting Q1 results. Other stocks also down in pre-market trading. Photo via Shutterstock.

Detailed price information for Aura Biosciences Inc (AURA-Q) from The Globe and Mail including charting and trades.